LB-100   Click here for help

GtoPdb Ligand ID: 11105

Synonyms: LB100
Compound class: Synthetic organic
Comment: LB-100 is a small molecule inhibitor of protein phosphatase 2A (PP2A) [3]. PP2A is a pivotal cellular switch that controls important events that impinge on cellular survival and death, such as cell cycle, apoptosis, and autophagy. PP2A acts on kinase substrates in a number of critical signal transduction pathways (including MAPK, Wnt, PI3K, NF&kappB, PKC, and Ca2+/calmodulin-dependent signalling pathways). PP2A is a validated oncology target. Studies have shown that LB-100 has anti-tumour activity [2] and can sensitise pancreatic cancer to chemotherapy [1] and radiotherapy [3].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 70.08
Molecular weight 268.14
XLogP -1.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)C(=O)C1[C@@H]2CC[C@H](C1C(=O)O)O2
Isomeric SMILES CN1CCN(CC1)C(=O)C1[C@@H]2CC[C@H](C1C(=O)O)O2
InChI InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)/t8-,9+,10?,11?/m0/s1
InChI Key JUQMLSGOTNKJKI-IZUQBHJASA-N
No information available.
Summary of Clinical Use Click here for help
LB-100 has advanced to clinical evaluation in solid tumours and myelodysplastic syndromes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03027388 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Phase 2 Interventional National Institutes of Health Clinical Center (CC)
NCT03886662 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Phase 1/Phase 2 Interventional Lixte Biotechnology Holdings, Inc.
NCT01837667 Phase I Study of LB-100 With Docetaxel in Solid Tumors Phase 1 Interventional Lixte Biotechnology Holdings, Inc.